This vaccine is already licensed for the prevention of high grade cervical dysplasia (CIN 2/3), high grade vulval dysplasia (VIN 2/3) and genital warts.
This extension will add prevention of high grade vaginal dysplasia (VaIN 2/3) to the indications for the vaccine. The Department of Health is due to announce which vaccine is to be used for the national HPV programme later this month but it would seem that there are distinct advantages to this vaccine over the bivalent alternative.
Action: Clinicians should be aware of the growing data to support HPV vaccination.
|« Steroids effective for gout||Drug Safety Update, Issue 11 »|